Money Makers Mentor

ESCAPE Bio Closes $73 Million in Financing

Clinical stage company, ESCAPE Bio, recently announced the closing of $73 million in financing. The San Francisco-based company develops treatments for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and dementia. Unlike other organizations of its kind, ESCAPE Bio uses an approach tailored to the needs of the patient.

According to President and CEO, Julie Anne Smith, the “generalized” approach to treatment in the neurodegenerative field often yields poor results. Diseases of this kind may manifest differently from patient-to-patient. Therefore, a more targeted approach is necessary for positive results.

The financing was led by Wellington Management Company LLP. For the purposes of privacy, the Boston-based firm declined to comment. Additional funding from CAM Capita…

Leave A Reply

Your email address will not be published.